Cytek Biosciences FY Conference Summary Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Cell analysis, specifically focusing on flow cytometers - **Growth Recognition**: Named one of the leading growth companies in the U.S. by Time Magazine [2][4] Key Financial Metrics - **Revenue**: $201.5 million in FY 2025, representing a 1% growth year-over-year despite a 4% decline in the overall flow cytometry market [4][11] - **Cash Position**: $261.5 million since going public, with positive cash flow generation [4][5] - **Market Share**: Cytek outperformed the market by gaining market share during a period of overall market decline [4][11] Product Launches and Innovations - **New Products**: - **Aurora Evo**: Launched in 2025, received positive feedback and is now a dominant product in sales [21][17] - **Muse Macro**: Awarded the BioTech Breakthrough Award of 2025 [2] - **Product Portfolio**: Broad range of instruments and reagents, including high-end products like Aurora Evo and CellSorter, and mid-level applications like Northern Lights and Muse Micro [12][17] Market Dynamics - **Flow Cytometry Market**: Estimated to grow from $5 billion to $9.2 billion by 2032, with a CAGR of 8.8% [11] - **Geographic Revenue Distribution**: - 47% from the U.S. - 28% from APAC - 25% from the rest of the world [7] - **Regional Growth**: APAC is expected to grow faster than the U.S., with government incentives driving investment in China [33] Customer Segments - **Revenue by Industry**: - 58% from pharma, biotech, and CROs - 42% from academic and government sectors [8] - **Customer Base**: Approximately 3,000 unique institutions and over 24,000 users on Cytek Cloud [3][14] Future Growth Drivers - **Service and Reagents**: Expected to grow at rates consistent with 2025, with a target of increasing recurring revenue from 34% to 40% over the next few years [17][24] - **Clinical Applications**: Expansion in Europe and China, with partnerships to drive clinical adoption [15][19] - **Installed Base**: Growing installed base is expected to generate consistent revenue growth [40] Challenges and Market Sentiment - **Funding Concerns**: Academic and government markets faced funding cuts, but sentiment has improved compared to the previous year [26][29] - **Pharma Spending**: While there were contractions in 2025, a return to growth is anticipated in 2026 as funding is reevaluated [28][30] Conclusion - **Strategic Positioning**: Cytek is well-positioned to capitalize on market growth through innovation, geographic expansion, and a diversified customer base. The company continues to outperform the market and is expected to maintain its growth trajectory in the coming years [10][39]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][14] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [6][24] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross margin of 53% compared to 59% in the prior year [17][18] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [20][22] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025 compared to the prior year, with a 26% growth in Q4 [8] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of reagents [10][16] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [16] Market Data and Key Metrics Changes - In the U.S., total revenue grew by 5% in Q4, driven by double-digit growth in service revenue, while EMEA grew 21% due to strong demand from academic and government customers [17] - APAC, including China, experienced a 15% growth in Q4, driven by increases in instruments, service, and reagents [17] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions by focusing on core strategic pillars: instrument, application, bioinformatics, and clinical [7] - The company plans to continue expanding its global footprint and enhancing its operational capabilities, including a new manufacturing facility in Singapore [11] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, particularly in academic and government spending, which contributed to the revenue growth in Q4 [42] - The company anticipates continued growth in 2026, with a revenue outlook of $205 million to $212 million, reflecting improved market conditions in EMEA and the U.S. [31][32] Other Important Information - The company reported a free cash flow of -$0.2 million in Q4, with total cash and marketable securities at $261.5 million as of December 31, 2025 [24][30] - The company repurchased approximately $15.1 million of its stock during 2025, reflecting a commitment to returning value to shareholders [30] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with some catch-up disbursements from the NIH [42][43] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [50] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in its sales teams and reagent sales force to drive future revenue growth [52][53]

Investor Presentation January 2026 Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek's market position and long-term market expansion opportunities; Cytek's business, product and operational goals and strategies; and Cytek's opp ...

Core Insights - BD (Becton, Dickinson and Company) has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to enhance research in deep human immune profiling and support the development of immune-mediated therapies [1][2] Group 1: Collaboration Details - The collaboration aims to develop and validate a high-parameter flow cytometry panel that captures key functional pathways in whole blood, including phosphorylation markers, to provide insights into single-cell responses to drugs or disease states [2] - A planned 1,000-patient immune profiling study will be conducted in partnership with the Penn Colton Center for Autoimmunity, expected to commence in the summer [2] - The project will utilize the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, and BD reagents, with BD teams managing reagents, instrumentation, and spectral data algorithms, while I3H teams will serve as scientific and clinical leads [2] Group 2: Technological Advancements - The BD FACSDiscover™ A8 Cell Analyzer is highlighted as the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, which will facilitate deeper insights into the human immune system [3] - The collaboration reflects a commitment to advancing science and health through the unlocking of the human immune system's potential [3] Group 3: Industry Impact - High-parameter single-cell studies are becoming increasingly central to understanding the human immune system, with BD's ecosystem of flow cytometers, single-cell systems, reagents, software, and informatics providing essential support for organizations like I3H [4] - The collaboration aims to translate immunological insights into quantitative, actionable information for discovery and clinical care teams globally [4]

Core Insights - Cytek Biosciences, Inc. has been awarded the title of Drug Discovery Solution of the Year for its Cytek Muse Micro cell analyzer at the 2025 BioTech Breakthrough Awards, recognizing its innovative contributions to the life sciences and biotechnology sectors [1][3][10] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Product Highlights - The Cytek Muse Micro cell analyzer enhances the original Guava Muse system, offering a compact, cost-effective, and multifunctional platform that simplifies flow cytometry while maintaining accuracy and versatility [2][4] - Applications of the Muse Micro system include cell counting, cell health and viability assessment, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis [2] Market Impact - The Muse Micro system aims to democratize access to sophisticated cell analysis, making it more accessible for smaller labs and resource-limited facilities, which traditionally faced barriers due to the complexity and cost of traditional flow cytometry systems [3][4]

Disease Diagnosis and Treatment - Hematopathology specializes in diagnosing diseases associated with blood, bone marrow, lymph nodes, and clotting mechanisms, utilizing advanced techniques like flow cytometry and molecular diagnostics [1] - Flow cytometry is used to convert cells into dots on a plot, aiding in the diagnosis and monitoring of blood cancers [3] - Measurable Residual Disease (MRD) detection via flow cytometry helps assess therapy effectiveness [4] - CAR T-cell therapy, where a patient's own immune cells are trained to fight cancer cells, shows promise in treating relapsed blood cancers [4] Technological Advancements - Flow cytometers use optics, fluidics, and electronics to analyze cells, detecting fluorescently labeled antibodies bound to antigens [3] - The integration of clinical knowledge, immunology, flow cytometry, and molecular biology is crucial for modern hematology [4] Impact and Training - Tata Memorial Center sees approximately 4,000 new blood cancer patients annually [4] - The center provides training to dozens of trainees, technicians, and pathologists from across the country and neighboring countries, focusing on understanding the science behind the data [4] - The ultimate goal is to provide patients with second chances, hope, and the opportunity to live out their dreams [4][5]